Lacosamide Tablet, Film Coated
Product Images NDC 68462-680

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 68462-680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc. Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-label (100mg Label)

FDA Label Image

150mg-label (150mg Label)

150mg-label (150mg Label)
This appears to be a packaging label for Glenmark's Lacosamide Tablets, used to treat epilepsy. The label provides information on the tablet dosage, company name, drug name and strength of the medication. It also has the Rx only note, indicating that the drug can only be dispensed with a prescription. Contact information for the company's customer service is included as well.*
FDA Label Image

200mg-label (200mg Label)

FDA Label Image

50mg-label (50mg Label)

FDA Label Image

Chemical-structure (Chemical Structure)

FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This appears to be a table showing the results of multiple studies comparing the effectiveness of a medication called Lacosamide with a placebo, with different dosages tested. The table shows that for some studies and dosages, there were statistically significant differences between Lacosamide and the placebo, but more information is needed to determine the specific findings of each study.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
This is a table depicting "Responder Rate" and "Improvement" and "Worsening" for different dosages of Lacosamide (anti-epileptic drug) and Placebo. The data is categorized based on the percentage of patients who show a response rate or improvement vs. worsening. The dosages being tested are 200mg/day, 400mg/day, and 600mg/day. The study has been conducted on a different number of patients for each dosage level.*
FDA Label Image
FDA Label Image

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.